Characteristics of patients
Specimen category . | Age, y/sex . | Disease duration, y . | Oral or IV corticosteroids per day, mg* . | Other immunosuppression . | Other anti-inflammatory drugs per day . | Histologic grading of inflammation† . |
|---|---|---|---|---|---|---|
| RA1 | 72/M | 21 | 10 | None | None | NA |
| RA2 | 49/F | 22 | 5 | Methotrexate 5 mg/wk | Ibuprofen 800 mg | NA |
| RA3 | 60/F | 20 | 3.75 | None | Ibuprofen 800 mg | NA |
| RA4 | 61/M | 40 | 5 | Methotrexate 17.5 mg/wk | None | NA |
| UC1 | 28/F | 10 | None | None | Mesalazine (5-ASA) 2.4 g | 3 |
| UC2 | 60/F | 14 | 15 | None | Sulfasalazine 2 g | 3 |
| UC3 | 32/M | 14 | 15 | None | None | 3 |
| UC4 | 44/F | 2 | 5 | Azathioprine 100 mg/d | Mesalazine (5-ASA) 1.5 g | 2 |
| UC5 | 12/M | 1 | 40 IV | Azathioprine 50 mg/d | Mesalazine (5-ASA) 1.5 g | 3 |
Specimen category . | Age, y/sex . | Disease duration, y . | Oral or IV corticosteroids per day, mg* . | Other immunosuppression . | Other anti-inflammatory drugs per day . | Histologic grading of inflammation† . |
|---|---|---|---|---|---|---|
| RA1 | 72/M | 21 | 10 | None | None | NA |
| RA2 | 49/F | 22 | 5 | Methotrexate 5 mg/wk | Ibuprofen 800 mg | NA |
| RA3 | 60/F | 20 | 3.75 | None | Ibuprofen 800 mg | NA |
| RA4 | 61/M | 40 | 5 | Methotrexate 17.5 mg/wk | None | NA |
| UC1 | 28/F | 10 | None | None | Mesalazine (5-ASA) 2.4 g | 3 |
| UC2 | 60/F | 14 | 15 | None | Sulfasalazine 2 g | 3 |
| UC3 | 32/M | 14 | 15 | None | None | 3 |
| UC4 | 44/F | 2 | 5 | Azathioprine 100 mg/d | Mesalazine (5-ASA) 1.5 g | 2 |
| UC5 | 12/M | 1 | 40 IV | Azathioprine 50 mg/d | Mesalazine (5-ASA) 1.5 g | 3 |
All patients with RA were positive for rheumatoid factor.
IV indicates intravenously; NA, not applicable.
Prednisolone taken orally if not otherwise indicated. Methylprednisolone was given intravenously.
Histologic grading of inflammation in the UC specimens was performed according to the following 0-4 scale: 0, normal mucosa; 1, no active inflammation; 2, mild active inflammation; 3, moderate active inflammation; and 4, severe active inflammation.23